Observation study to examine the efficacy of 500mg Fluvestrant that targets ER(+) postmenopausal metastatic breast cancer patients (>1st line).
Not Applicable
- Conditions
- ER-positive postmenopausal metastatic/inoperable breast cancer
- Registration Number
- JPRN-UMIN000011976
- Lead Sponsor
- PerSeUS:Perpetual Study estimated -by United Sections in Gifu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
1.Life threatening including large liver metastasis, larege brain metastasis, systematic inflammatory lymphangitis in lung. 2.Inflammatory breast cancer 3.Previous therapy by Fluvestrant. 4.Patients who accetted >4th ET. 5. Allergy to Fluvestrant. 6.Patients considered ineligible by the attending physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Clinicalbenefitrate Overallresponse rate Safety